title: Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines.
abstract: BACKGROUND
  Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression and other HHV8-associated diseases such as Kaposi's sarcoma (KS). The prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival. The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not included in current chemotherapy treatment protocols.
  
  
  METHODS
  We have analyzed 11 cell lines against 27 frequently used cytostatic drugs in short term (3 days) survival assays using automated high throughput confocal microscopy.
  
  
  RESULTS
  All cell lines showed a distinct, individual drug sensitivity pattern. Considering the in vitro used and clinically achieved drug concentration, Vinorelbine, Paclitaxel, Epirubicin and Daunorubicin were the most effective drugs.
  
  
  CONCLUSIONS
  We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The heterogeneity in the drug response pattern however indicated that assay-guided individualized therapy might be required to optimize therapeutic response.
authors: Department of Microbiology, Tumor and Cell Biology-MTC and Center for Integrative Recognition in the Immune System-IRIS, Karolinska Institute, Box 280 SE-17177 Stockholm, Sweden. rita.otvos@ki.se
authors: Rita
authors: R
authors: Otvös
authors: Henriette
authors: H
authors: Skribek
authors: Lorand L
authors: LL
authors: Kis
authors: Annunziata
authors: A
authors: Gloghini
authors: Laszlo
authors: L
authors: Markasz
authors: Emilie
authors: E
authors: Flaberg
authors: Staffan
authors: S
authors: Eksborg
authors: Jozsef
authors: J
authors: Konya
authors: Lajos
authors: L
authors: Gergely
authors: Antonino
authors: A
authors: Carbone
authors: Laszlo
authors: L
authors: Szekely
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D016000:Cluster Analysis; D019008:Drug Resistance, Neoplasm; D015658:HIV Infections / Q000150:complications; D006566:Herpesviridae Infections / Q000150:complications; D019288:Herpesvirus 8, Human; D006801:Humans; D054685:Lymphoma, Primary Effusion / Q000188:drug therapy* / Q000821:virology*; D008297:Male
chemical_list: D000970:Antineoplastic Agents